



## Treximet® (sumatriptan/naproxen) – First-time generic

- On November 21, 2017, Macoven Pharmaceuticals launched an authorized generic version of Pernix Therapeutics' [Treximet \(sumatriptan/naproxen\)](#) 85 mg/500 mg tablets, for the acute treatment of migraine attacks with or without aura in adults and pediatric patients ≥ 12 years of age.
  - Treximet should only be used if a clear diagnosis of migraine headache has been established. If a patient has no response to the first migraine attack treated with Treximet, reconsider the diagnosis of migraine before Treximet is administered to treat any subsequent attacks.
  - Treximet is not indicated for the prevention of migraine attacks. The safety and effectiveness of Treximet have not been established for the treatment of cluster headache.
- Brand Treximet is also currently available as a 10 mg/60 mg tablet.
- Treximet carries a boxed warning regarding risks of serious cardiovascular and gastrointestinal events.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](http://optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2017 Optum, Inc. All rights reserved.